Skip to main content
Erschienen in: Medical Oncology 2/2013

01.06.2013 | Original Paper

Expression of survivin and its four splice variants in colorectal cancer and its clinical significances

verfasst von: Quan-Xing Ge, Yu-Yuan Li, Yu-Qiang Nie, Wen-Ge Zuo, Yan-Lei Du

Erschienen in: Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to investigate the clinical significances of the mRNA expression of survivin gene and its four splice variants in the pathogenesis of colorectal cancer (CRC). CRC samples, matched adjacent tissues, and normal tissues were collected from surgical resections of 39 patients with histologically confirmed diagnosis. The mRNA expression of survivin and its four splice variants, that is, survivin-△Ex3, survivin-2B, survivin-3B, and survivin-2α, was detected using semiquantitative PCR and RT-PCR. Carcinoembryonic antigen (CEA) CAM5 was determined as control. The mRNA expression rates of survivin, survivin-△Ex3, survivin-2B, survivin-3B, surviving-2α, and CEA CAM5 in CRC samples were significantly higher than those in adjacent tissues (P < 0.01) and those in normal tissues (P < 0.01). The mRNA levels of the above variants in CRC samples were also significantly higher than those in adjacent tissues (P < 0.01) and those in normal tissues (P < 0.01). The mRNA levels of survivin, survivin-2B, and survivin-2α were not associated with any clinical variable of patients, while the levels of survivin-△Ex3 and survivin-3B were associated with lymphoid metastasis and Dukes grade (P < 0.05), and survivin-△Ex3 was associated with invasiveness. We concluded that mRNA expression rates and levels of survivin and its four splice variants elevated in CRC tissues, and expression levels of survivin-△Ex3 and survivin-3B were positively associated with tumor aggression.
Literatur
2.
Zurück zum Zitat Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough? Ann Oncol: official journal of the European Society for Medical Oncology/ESMO. 2003;14(7):1026–38.CrossRef Graziano F, Cascinu S. Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes’ B colorectal cancer patients: how much evidence is enough? Ann Oncol: official journal of the European Society for Medical Oncology/ESMO. 2003;14(7):1026–38.CrossRef
3.
Zurück zum Zitat Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2005;23(15):3526–35. doi:10.1200/JCO.2005.00.695.CrossRef Eschrich S, Yang I, Bloom G, Kwong KY, Boulware D, Cantor A, Coppola D, Kruhoffer M, Aaltonen L, Orntoft TF, Quackenbush J, Yeatman TJ. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol: official journal of the American Society of Clinical Oncology. 2005;23(15):3526–35. doi:10.​1200/​JCO.​2005.​00.​695.CrossRef
5.
Zurück zum Zitat Reed JC, Bischoff JR. BIRinging chromosomes through cell division–and survivin’ the experience. Cell. 2000;102(5):545–8.PubMedCrossRef Reed JC, Bischoff JR. BIRinging chromosomes through cell division–and survivin’ the experience. Cell. 2000;102(5):545–8.PubMedCrossRef
8.
Zurück zum Zitat Mitchell PJ, Ravi S, Grifftiths B, Reid F, Speake D, Midgley C, Mapstone N. Multicentre review of lymph node harvest in colorectal cancer: are we understaging colorectal cancer patients? Int J Colorectal Dis. 2009;24(8):915–21. doi:10.1007/s00384-009-0697-z.PubMedCrossRef Mitchell PJ, Ravi S, Grifftiths B, Reid F, Speake D, Midgley C, Mapstone N. Multicentre review of lymph node harvest in colorectal cancer: are we understaging colorectal cancer patients? Int J Colorectal Dis. 2009;24(8):915–21. doi:10.​1007/​s00384-009-0697-z.PubMedCrossRef
9.
Zurück zum Zitat Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res. 2003;23(4):3327–31.PubMed Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, de Kok JB. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res. 2003;23(4):3327–31.PubMed
10.
11.
Zurück zum Zitat Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, Wheatley SP. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem. 2006;281(2):1286–95. doi:10.1074/jbc.M508773200.PubMedCrossRef Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, Wheatley SP. Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem. 2006;281(2):1286–95. doi:10.​1074/​jbc.​M508773200.PubMedCrossRef
12.
Zurück zum Zitat Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2003;9(3):931–46. Williams NS, Gaynor RB, Scoggin S, Verma U, Gokaslan T, Simmang C, Fleming J, Tavana D, Frenkel E, Becerra C. Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays and RNA interference. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2003;9(3):931–46.
13.
Zurück zum Zitat Pavlidou A, Dalamaga M, Kroupis C, Konstantoudakis G, Belimezi M, Athanasas G, Dimas K. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J gastroenterol: WJG. 2011;17(12):1614–21. doi:10.3748/wjg.v17.i12.1614.PubMedCrossRef Pavlidou A, Dalamaga M, Kroupis C, Konstantoudakis G, Belimezi M, Athanasas G, Dimas K. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR. World J gastroenterol: WJG. 2011;17(12):1614–21. doi:10.​3748/​wjg.​v17.​i12.​1614.PubMedCrossRef
14.
Zurück zum Zitat Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009;24(8):875–84. doi:10.1007/s00384-009-0725-z.PubMedCrossRef Fang YJ, Lu ZH, Wang GQ, Pan ZZ, Zhou ZW, Yun JP, Zhang MF, Wan DS. Elevated expressions of MMP7, TROP2, and survivin are associated with survival, disease recurrence, and liver metastasis of colon cancer. Int J Colorectal Dis. 2009;24(8):875–84. doi:10.​1007/​s00384-009-0725-z.PubMedCrossRef
15.
Zurück zum Zitat Xi RC, Biao WS, Gang ZZ. Significant elevation of survivin and living expression in human colorectal cancer: inverse correlation between expression and overall survival. Onkologie. 2011;34(8–9):428–32. doi:10.1159/000331132.PubMedCrossRef Xi RC, Biao WS, Gang ZZ. Significant elevation of survivin and living expression in human colorectal cancer: inverse correlation between expression and overall survival. Onkologie. 2011;34(8–9):428–32. doi:10.​1159/​000331132.PubMedCrossRef
16.
Zurück zum Zitat Abd El-Hameed A. Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst. 2005;17(1):42–50.PubMed Abd El-Hameed A. Survivin expression in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst. 2005;17(1):42–50.PubMed
17.
Zurück zum Zitat Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF, Chiang H, Jin JS. Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters. Dis Markers. 2009;26(1):9–18. doi:10.3233/DMA-2009-0598.PubMed Lee YY, Yu CP, Lin CK, Nieh S, Hsu KF, Chiang H, Jin JS. Expression of survivin and cortactin in colorectal adenocarcinoma: association with clinicopathological parameters. Dis Markers. 2009;26(1):9–18. doi:10.​3233/​DMA-2009-0598.PubMed
19.
Zurück zum Zitat Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006;6(4):305–11. doi:10.3816/CCC.2006.n.049.PubMedCrossRef Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer. Clin Colorectal Cancer. 2006;6(4):305–11. doi:10.​3816/​CCC.​2006.​n.​049.PubMedCrossRef
20.
Zurück zum Zitat Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol. 2012;105(6):520–8. doi:10.1002/jso.22134.PubMedCrossRef Chu XY, Chen LB, Wang JH, Su QS, Yang JR, Lin Y, Xue LJ, Liu XB, Mo XB. Overexpression of survivin is correlated with increased invasion and metastasis of colorectal cancer. J Surg Oncol. 2012;105(6):520–8. doi:10.​1002/​jso.​22134.PubMedCrossRef
21.
Zurück zum Zitat Kim K, Chie EK, Wu HG, Kim SG, Lee SH, Kang GH, Hyun CL, Ha SW. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. 2011;26(8):1019–23. doi:10.1007/s00384-011-1180-1.PubMedCrossRef Kim K, Chie EK, Wu HG, Kim SG, Lee SH, Kang GH, Hyun CL, Ha SW. High survivin expression as a predictor of poor response to preoperative chemoradiotherapy in locally advanced rectal cancer. Int J Colorectal Dis. 2011;26(8):1019–23. doi:10.​1007/​s00384-011-1180-1.PubMedCrossRef
22.
Zurück zum Zitat Fraunholz I, Rodel C, Distel L, Rave-Frank M, Kohler D, Falk S, Rodel F. High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. Radiat Oncol. 2012;7:88. doi:10.1186/1748-717X-7-88.PubMedCrossRef Fraunholz I, Rodel C, Distel L, Rave-Frank M, Kohler D, Falk S, Rodel F. High survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. Radiat Oncol. 2012;7:88. doi:10.​1186/​1748-717X-7-88.PubMedCrossRef
23.
Zurück zum Zitat Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91(11):2026–32.PubMedCrossRef Kawasaki H, Toyoda M, Shinohara H, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Tenjo T, Tanigawa N. Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis. Cancer. 2001;91(11):2026–32.PubMedCrossRef
24.
Zurück zum Zitat Chen WC, Liu Q, Fu JX, Kang SY. Expression of survivin and its significance in colorectal cancer. World J Gastroenterol: WJG. 2004;10(19):2886–9.PubMed Chen WC, Liu Q, Fu JX, Kang SY. Expression of survivin and its significance in colorectal cancer. World J Gastroenterol: WJG. 2004;10(19):2886–9.PubMed
25.
Zurück zum Zitat Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG, Ma T. Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol: WJG. 2003;9(5):974–7.PubMed Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG, Ma T. Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol: WJG. 2003;9(5):974–7.PubMed
26.
Zurück zum Zitat Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep. 2005;13(5):891–7.PubMed Suga K, Yamamoto T, Yamada Y, Miyatake S, Nakagawa T, Tanigawa N. Correlation between transcriptional expression of survivin isoforms and clinicopathological findings in human colorectal carcinomas. Oncol Rep. 2005;13(5):891–7.PubMed
27.
Zurück zum Zitat Yie SM, Lou B, Ye SR, Cao M, He X, Li P, Hu K, Rao L, Wu SM, Xiao HB, Gao E. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15(11):3073–82. doi:10.1245/s10434-008-0069-x.PubMedCrossRef Yie SM, Lou B, Ye SR, Cao M, He X, Li P, Hu K, Rao L, Wu SM, Xiao HB, Gao E. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse. Ann Surg Oncol. 2008;15(11):3073–82. doi:10.​1245/​s10434-008-0069-x.PubMedCrossRef
28.
Zurück zum Zitat Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol. 2007;4(3):174–91.PubMedCrossRef Sampath J, Pelus LM. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol. 2007;4(3):174–91.PubMedCrossRef
29.
Zurück zum Zitat Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59(24):6097–102.PubMed Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res. 1999;59(24):6097–102.PubMed
30.
Zurück zum Zitat Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun. 2004;314(3):902–7.PubMedCrossRef Badran A, Yoshida A, Ishikawa K, Goi T, Yamaguchi A, Ueda T, Inuzuka M. Identification of a novel splice variant of the human anti-apoptosis gene survivin. Biochem Biophys Res Commun. 2004;314(3):902–7.PubMedCrossRef
32.
Zurück zum Zitat Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, Hirokawa K, Kitagawa M. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res. 2004;28(5):487–94. doi:10.1016/j.leukres.2003.10.013.PubMedCrossRef Nakagawa Y, Yamaguchi S, Hasegawa M, Nemoto T, Inoue M, Suzuki K, Hirokawa K, Kitagawa M. Differential expression of survivin in bone marrow cells from patients with acute lymphocytic leukemia and chronic lymphocytic leukemia. Leuk Res. 2004;28(5):487–94. doi:10.​1016/​j.​leukres.​2003.​10.​013.PubMedCrossRef
33.
Zurück zum Zitat Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol: WJG. 2004;10(22):3245–50.PubMed Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol: WJG. 2004;10(22):3245–50.PubMed
34.
Zurück zum Zitat Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol. 2000;35(6):550–3.PubMedCrossRef Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol. 2000;35(6):550–3.PubMedCrossRef
35.
Zurück zum Zitat Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer (J int cancer). 2002;100(1):30–6. doi:10.1002/ijc.10450.CrossRef Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer (J int cancer). 2002;100(1):30–6. doi:10.​1002/​ijc.​10450.CrossRef
37.
Zurück zum Zitat Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer. 2002;86(5):737–43. doi:10.1038/sj.bjc.6600153.PubMedCrossRef Krieg A, Mahotka C, Krieg T, Grabsch H, Muller W, Takeno S, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer. 2002;86(5):737–43. doi:10.​1038/​sj.​bjc.​6600153.PubMedCrossRef
38.
Zurück zum Zitat Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 2002;9(12):1334–42. doi:10.1038/sj.cdd.4401091.PubMedCrossRef Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ. 2002;9(12):1334–42. doi:10.​1038/​sj.​cdd.​4401091.PubMedCrossRef
40.
Zurück zum Zitat Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane–resistant ovarian cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2011;17(11):3716–26. doi:10.1158/1078-0432.CCR-11-0233.CrossRef Vivas-Mejia PE, Rodriguez-Aguayo C, Han HD, Shahzad MM, Valiyeva F, Shibayama M, Chavez-Reyes A, Sood AK, Lopez-Berestein G. Silencing survivin splice variant 2B leads to antitumor activity in taxane–resistant ovarian cancer. Clin Cancer Res: an official journal of the American Association for Cancer Research. 2011;17(11):3716–26. doi:10.​1158/​1078-0432.​CCR-11-0233.CrossRef
41.
Zurück zum Zitat Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP. The survivin-31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst). 2010;. doi:10.3233/ACP-2010-0537. Antonacopoulou AG, Floratou K, Bravou V, Kottorou A, Dimitrakopoulos FI, Marousi S, Stavropoulos M, Koutras AK, Scopa CD, Kalofonos HP. The survivin-31 snp in human colorectal cancer correlates with survivin splice variant expression and improved overall survival. Anal Cell Pathol (Amst). 2010;. doi:10.​3233/​ACP-2010-0537.
42.
Zurück zum Zitat De Maria S, Pannone G, Bufo P, Santoro A, Serpico R, Metafora S, Rubini C, Pasquali D, Papagerakis SM, Staibano S, De Rosa G, Farina E, Emanuelli M, Santarelli A, Mariggio MA, Lo Russo L, Lo Muzio L. Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(1):107–16. doi:10.1007/s00432-008-0433-z.PubMedCrossRef De Maria S, Pannone G, Bufo P, Santoro A, Serpico R, Metafora S, Rubini C, Pasquali D, Papagerakis SM, Staibano S, De Rosa G, Farina E, Emanuelli M, Santarelli A, Mariggio MA, Lo Russo L, Lo Muzio L. Survivin gene-expression and splicing isoforms in oral squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(1):107–16. doi:10.​1007/​s00432-008-0433-z.PubMedCrossRef
43.
Zurück zum Zitat Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, Klein-Hitpass L, Kovacs AF, Doring C, Hansmann ML, Hofmann WK, Kunkel M, Brochhausen C, Engels K, Lippert BM, Mann W, Stauber RH. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle. 2007;6(12):1502–9.PubMedCrossRef Knauer SK, Bier C, Schlag P, Fritzmann J, Dietmaier W, Rodel F, Klein-Hitpass L, Kovacs AF, Doring C, Hansmann ML, Hofmann WK, Kunkel M, Brochhausen C, Engels K, Lippert BM, Mann W, Stauber RH. The survivin isoform survivin-3B is cytoprotective and can function as a chromosomal passenger complex protein. Cell Cycle. 2007;6(12):1502–9.PubMedCrossRef
44.
Zurück zum Zitat Sawai K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol Res. 2010;18(11–12):541–7.PubMedCrossRef Sawai K, Goi T, Hirono Y, Katayama K, Yamaguchi A. Survivin-3B gene decreases the invasion-inhibitory effect of colon cancer cells with 5-fluorouracil. Oncol Res. 2010;18(11–12):541–7.PubMedCrossRef
Metadaten
Titel
Expression of survivin and its four splice variants in colorectal cancer and its clinical significances
verfasst von
Quan-Xing Ge
Yu-Yuan Li
Yu-Qiang Nie
Wen-Ge Zuo
Yan-Lei Du
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0535-6

Weitere Artikel der Ausgabe 2/2013

Medical Oncology 2/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.